1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsAccelerating Malaria Vaccine and Monoclonal Antibody Discovery (NOSI) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID). This Notice of Special Interest (NOSI) encourages research that generates new malaria vaccine candidates or monoclonal antibody (mAb)-based interventions, especially for *Plasmodium falciparum* and *P. vivax*.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
New NOSI Prioritizes Malaria Vaccine and Monoclonal Antibody Discovery | NIAID: National Institute of Allergy and Infectious Diseases Resources for Researchers Division of Intramural Research Labs Research at Vaccine Research Center Intramural Scientist & Clinician Directory Research Rules & Policies Allergy, Immunology & Transplantation Resources for Researchers Antimicrobial (Drug) Resistance Antimicrobial Resistance Threats Information for Researchers Risk Factors & Prevention Research Immune Tolerance Processes Disease-Specific Research Information for Researchers Autoimmune Lymphoproliferative Syndrome (ALPS) Basic & Preclinical Research Information for Researchers Information for Researchers Shiga Toxin-Producing E.
coli (STEC) Researching Ebola in Africa Information for Researchers Information for Researchers Why Food Allergy is a Priority for NIAID Characterizing Food Allergy & Addressing Related Disorders Information for Researchers Diagnosis & Management Guidelines Disease-Specific Research Information for Researchers Genomics & Advanced Technologies Pathogen-Based Initiatives Information for Researchers Information for Researchers Group A Streptococcal Infections Disease-Specific Research Information for Researchers Overview of the Immune System Features of an Immune Response Information for Researchers Information for Researchers Leprosy (Hansen's Disease) How NIAID is Addressing Lyme Disease Information for Researchers Parasite, Mosquito & Human Host Prevention, Treatment & Control Strategies Strategic Partnerships & Research Capacity Information for Researchers Information for Researchers Neglected Tropical Diseases Information for Researchers Translational & Clinical Research Cross-cutting Preparedness Molecular & Genetic Research Primary Immune Deficiency Diseases (PIDDs) Information for Researchers Animal Prion Diseases and Humans Information for Researchers Respiratory Syncytial Virus (RSV) Schistosomiasis (Bilharzia) Research in Endemic Regions Sexually Transmitted Infections (STIs) NIAID's Research Approach Information for Researchers Disease-Specific Research Information for Researchers Information for Researchers Disease-Specific Vaccines Information for Researchers Translational & Clinical Research Information for Researchers Biology, Genetics & Clinical Research NIAID's Approach to Women's Health Research Sex-Specific Health Challenges Facing Women Biennial Report (FY 2019-2020) Information for Researchers Why NIAID Is Researching Zika Virus Information for Researchers Find a Funding Opportunity Opportunities & Announcements NIAID Research Priorities Plan Your Budget & Personnel Additional Application Elements Research with Special Considerations After You Submit an Application Funding Policies and Considerations Understand the Review Process Respond to Pre-Award Requests Negotiation & Initial Award Become a Healthy Volunteer Participant's Guide to Clinical Trials HIV and Emerging Infectious Diseases Laboratory of Infectious Diseases Primary Immune Deficiency Clinic Vaccine Research Center Clinical Studies Fill Out the Volunteer Form Q&A: Vaccine Clinical Studies Vaccine Clinical Studies Safeguards Clinical Trial Publications NIAID-Funded Research News Division of Allergy, Immunology, and Transplantation Division of Microbiology and Infectious Diseases Division of Extramural Activities Division of Clinical Research Division of Intramural Research Dr. Joseph J.
Kinyoun: Father of the NIH Dr. Joseph Kinyoun The Indispensable Forgotten Man Dr. Joseph Kinyoun: Selected Bibliography NIAID 60th Anniversary Timeline Research Training at NIAID Campuses Grant Programs that NIAID Funds AIDS Research Advisory Committee AIDS Vaccine Research Subcommittee Board of Scientific Counselors Members Advisory and Peer Review Committees Autoimmune Diseases Committee Website Policies and Notices External Link Icon and Disclaimers Freedom of Information Act (FOIA) Voluntarily Submitted Information New NOSI Prioritizes Malaria Vaccine and Monoclonal Antibody Discovery Funding News Editions: December 18, 2024 See more articles in this edition Apply to NIAID’s Notice of Special Interest (NOSI): Accelerating Malaria Vaccine and Monoclonal Antibody Discovery if you can propose research that helps generate new malaria vaccine candidates or monoclonal antibody (mAb)-based interventions, especially for Plasmodium falciparum and P.
vivax . Recently, the World Health Organization (WHO) recommended two malaria vaccines, RTS/AS01E and R21/Matrix M, for broad introduction in African countries for children older than 5 months. To address future effective global malaria control and elimination, WHO issued revised Preferred Product Characteristics (PPC) calling for new strategic priorities for next generation malaria vaccines.
Research Objectives and Scope Currently, due to significant scientific and technical challenges facing malaria research and development, there are very few preclinical and clinical candidates in the global development pipeline that possess promising features that meet the PPC-defined criteria.
NIAID encourages applications focused on “combination” vaccine concepts to improve efficacy, targeting one or more parasite antigens of the different life cycle stages (i.e., pre-erythrocytic stage, blood, or sexual stage) of the parasites. Research Areas of Interest NIAID is most interested in the research topics listed below. Identifying, characterizing, credentialing, or validating novel protective malaria antigens/peptides/epitopes.
Molecular immunogen design and testing using cutting-edge innovations (e.g., artificial intelligence, machine learning, cryo-electron microscopy, structural immunobiology). Discovering new vaccine candidates based on novel technology platforms, adjuvants, or vaccination strategies. Constructing novel whole organism-based malaria vaccines or improvements to existing whole organism-based malaria vaccines.
Discovering novel vaccine candidates or formulations that exhibit improved performance, manufacturability, or deliverability over existing vaccines. Discovering new vaccine candidates or improvement of existing vaccine candidates to have more favorable storage conditions, or administration and deployment features. Screening, testing, credentialing, or validating new vaccine candidates or formulations with novel assays or animal models.
For mAbs or novel Ab-based interventions: Identifying and characterizing new functional mAbs, including broadly protective mAbs. Antibody engineering to improve functionality or stability, such as affinity/avidity, pharmacokinetic durability, or manufacturability.
Developing novel platforms or strategies to express or deliver Abs or Ab-based products, including construction and testing of Ab-based concepts, such as viral-vectored, mRNA expressed, or bi- or multi-specific Ab constructs for improved product features to enhance prevention of malaria infection or transmission, or ameliorate malaria disease.
Application and Submission Information This notice applies to application receipt dates on or after February 5, 2025, and subsequent receipt dates through November 16, 2027. NIH Research Project Grant (Parent R01, Clinical Trial Not Allowed) NIH Exploratory/Developmental Research Grant Program (Parent R21, Clinical Trial Not Allowed) Follow all instructions in the SF 424 (R&R) Application Guide and the NOFO you use to apply.
You must include “ NOT-AI-24-072 ” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF 424 R&R form. Direct all inquiries to NIAID’s scientific/research contact, Dr. Annie Mo, at moa@niaid. nih.
gov or 240-627-3320. Content last reviewed on December 18, 2024
According to the current listing, eligibility includes: This notice applies to applications through various NIH funding opportunities, including the NIH Research Project Grant (Parent R01, Clinical Trial Not Allowed). Confirm the full requirements in the official notice before applying.
Applications for Accelerating Malaria Vaccine and Monoclonal Antibody Discovery (NOSI) are due November 16, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Accelerating Malaria Vaccine and Monoclonal Antibody Discovery (NOSI) is funded by National Institute of Allergy and Infectious Diseases (NIAID). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articleThe ReVAMPP network funds vaccine and monoclonal antibody research across five virus families. Here is who won, what the prototype-pathogen strategy means, and how to position for the next round.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article